{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:46Z","timestamp":1785308326051,"version":"3.55.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Chronic myeloid leukemia (CML) with megakaryoblastic blast crisis (MKBC) as the initial manifestation is extremely rare, accounting for less than 3% of all CML cases. Philadelphia chromosome-positive acute myeloid leukemia, FAB M7 subtype (Ph+ AML-M7), is also known as Philadelphia chromosome-positive acute megakaryoblastic leukemia (Ph+ AMKL), representing a distinct and prognostically unfavorable category of AML. Morphologically and immunophenotypically, these two entities are nearly identical, posing significant diagnostic challenges. We describe a novel case of Ph+ leukemia with MKBC differentiation that appears most consistent with CML in blast phase (BP). Following treatment with a tyrosine kinase inhibitor (TKI) combined with induction and consolidation chemotherapy, the patient achieved complete remission (CR). Although hematopoietic stem cell transplantation (HSCT) was declined due to economic constraints, the patient has maintained deep molecular remission(MR5, BCR::ABL1\n                    <jats:sup>IS<\/jats:sup>\n                    \u2264 0.001%)for 35 months to date. Through a systematic review of existing literature, this article elucidates key discriminative features between the two conditions and proposes a practical diagnostic and therapeutic framework to guide clinical decision-making.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1812840","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:53Z","timestamp":1785304733000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Distinguishing chronic myeloid leukemia in megakaryocytic blast crisis from de novo Ph+ acute megakaryoblastic leukemia: a case report and systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Qingqing","family":"Liu","sequence":"first","affiliation":[{"name":"The First Clinical Medical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Yu","sequence":"additional","affiliation":[{"name":"The First Clinical Medical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]},{"name":"Department of Hematology, the Shunde Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenghui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000004671","article-title":"Chronic myeloid and lymphocytic leukemias in the elderly: public health challenges in early detection and long-term care","volume":"88","author":"Obeagu","year":"2026","journal-title":"Ann Med Surg (Lond)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/MS9.0000000000004412","article-title":"Late-stage leukemias in aging populations: a public health call for integrated and personalized care models","volume":"88","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.07.004","article-title":"Megakaryocytic blast crisis in chronic myeloid leukiemia: an uncommon presentation in a common neoplasm","volume":"44","author":"Agrawal","year":"2022","journal-title":"Hematol Transfus Cell Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199604000-00016","article-title":"Chronic myeloid leukemia manifested during megakaryoblastic crisis","volume":"89","author":"Wu","year":"1996","journal-title":"South Med J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982695","article-title":"Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis","volume":"76","author":"Hirose","year":"2002","journal-title":"Int J Hematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1034\/j.1600-0609.2002.01638.x","article-title":"Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia","volume":"69","author":"Flores Pelloso","year":"2002","journal-title":"Eur J Haematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20797","article-title":"Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia","volume":"82","author":"Campiotti","year":"2007","journal-title":"Am J Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20777","article-title":"Paraplegia as the presenting manifestation of extramedullary megakaryoblastic transformation of previously undiagnosed chronic myelogenous leukemia","volume":"82","author":"Bryant","year":"2007","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.02.025","article-title":"Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia","volume":"32","author":"Pullarkat","year":"2008","journal-title":"Leukemia Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1658-3876(10)50056-6","article-title":"Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia","volume":"3","author":"Al-Shehri","year":"2010","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-85516-3_1065","article-title":"A case report of acute megakaryocytic leukemia transformed from chronic myelogenous leukemia","volume":"31","author":"Lu","year":"2011","journal-title":"Chin J Pract Internal Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2013.375","article-title":"A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7)","volume":"7","author":"Karkuzhali","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02628-8","article-title":"Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Sasaki","year":"2019","journal-title":"Int J Hematol"},{"key":"B16","article-title":"Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features","volume":"81","author":"Cuneo","year":"1996","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.0887b.x","article-title":"The Philadelphia chromosome as a secondary abnormality in two cases of acute myeloid leukemia","volume":"102","author":"Mozziconacci","year":"1998","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-003-0783-1","article-title":"Acute megakaryoblastic leukaemia with extreme thrombocytosis and p190(bcr\/abl)rearrangement","volume":"83","author":"Balatzenko","year":"2004","journal-title":"Ann Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1309\/B4NVER1AJJ84CTUU","article-title":"Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis","volume":"127","author":"Soupir","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.03.032","article-title":"Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression","volume":"34","author":"Papageorgiou","year":"2010","journal-title":"Leuk Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.1004-2806.2014.09.021","article-title":"Philadelphia-chromosome-positive acute megakaryoblastic leukemia: a case report and review of literatures","volume":"27","author":"Han","year":"2014","journal-title":"J Clin Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.04.020","article-title":"Impact of an additional chromosome on the clinical outcomes of hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia in adults","volume":"24","author":"Min","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.7335-21","article-title":"Acute megakaryoblastic leukemia harboring a subclone expressing BCR-ABL1 fusion gene product","volume":"60","author":"Kashima","year":"2021","journal-title":"Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309047856","article-title":"The cytogenetic scenario of chronic myeloid leukemia","author":"Mitelman","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1200\/JCO.1996.14.1.196","article-title":"Significance of cytogenetic clonal evolution in chronic myelogenous leukemia","volume":"14","author":"Majlis","year":"1996","journal-title":"J Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-052282","article-title":"A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia","volume":"110","author":"Gu","year":"2007","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26188812","article-title":"Unveiling cryptic BCR-ABL1 rearrangements: diagnostic challenges and clinical impact in myeloid Malignancies","volume":"26","author":"Ferrari","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8917","article-title":"A rare presentation of BCR\u2010ABL1 and RUNX1\u2010MECOM rearrangement in a pediatric patient with acute myeloid leukemia","volume":"12","author":"Alamri","year":"2024","journal-title":"Clin Case Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18515","article-title":"Secondary fusion proteins as a mechanism of BCR::ABL1 kinase-independent resistance in chronic myeloid leukemia","volume":"200","author":"Barnes","year":"2023","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.7.2304","article-title":"Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia","volume":"99","author":"Wadhwa","year":"2002","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.7.1079","article-title":"High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis","volume":"4","author":"Iacoboni","year":"1986","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402775","article-title":"Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs","volume":"16","author":"Tipping","year":"2002","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.11.004","article-title":"The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)","volume":"35","author":"Deau","year":"2011","journal-title":"Leukemia Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"B42","volume-title":"Clinical Practice Guidelines in Oncology on Acute Myeloid Leukemia","author":"Pollyea","year":"2025"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18370","article-title":"Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity","volume":"199","author":"Copland","year":"2022","journal-title":"Br J Haematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.057513","article-title":"Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation","volume":"97","author":"Milojkovic","year":"2012","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21032","article-title":"Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience","volume":"103","author":"Kantarjian","year":"2005","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22535","article-title":"Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis","volume":"109","author":"Fruehauf","year":"2007","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404115","article-title":"High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia","volume":"20","author":"Rea","year":"2006","journal-title":"Leukemia"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830430104","article-title":"High incidence of meningeal leukemia in lymphoid blast crisis of chronic myelogenous leukemia","volume":"43","author":"Saikia","year":"1993","journal-title":"Am J Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated effluxSTI-571","volume":"304","author":"Dai","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0097","article-title":"An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse","volume":"11","author":"Lindhorst","year":"2013","journal-title":"J Natl Compr Cancer Network"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"H","year":"2006","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026311","article-title":"Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"145","author":"Guilhot","year":"2025","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0188","article-title":"Management of advanced-phase chronic myelogenous leukemia","volume":"14","author":"Radich","year":"2016","journal-title":"J Natl Compr Cancer Network"},{"key":"B55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-139452","article-title":"The outcome of patients with advanced phase chronic myeloid leukemia with and without allogeneic hemopoietic stem cell transplantation","volume":"136","author":"Morozova","year":"2020","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.48","article-title":"RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation","volume":"23","author":"Kuo","year":"2009","journal-title":"Leukemia"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-223982","article-title":"AML1\/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms","volume":"114","author":"Ding","year":"2009","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.288","article-title":"The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics","volume":"27","author":"Abdel-Wahab","year":"2013","journal-title":"Leukemia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","volume":"3","author":"Menezes","year":"2013","journal-title":"Blood Cancer J"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1340726","article-title":"Tyrosine phosphatase PTPN11\/SHP2 in solid tumors - bull\u2019s eye for targeted therapy","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1042\/BST20210363","article-title":"In the spotlight: the role of TGF\u03b2 signalling in haematopoietic stem and progenitor cell emergence","volume":"50","author":"Thambyrajah","year":"2022","journal-title":"Biochem Soc Trans"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1182\/blood-2024-209075","article-title":"Outcomes of patients with chronic myeloid leukemia who underwent allogeneic stem cell transplantation in the tyrosine kinase inhibitors era","volume":"144","author":"Wernicke","year":"2024","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1812840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:55Z","timestamp":1785304735000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1812840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2026.1812840"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1812840","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1812840"}}